Harvard Mouse

(redirected from Oncomouse)
Also found in: Dictionary, Encyclopedia, Wikipedia.
A genetically engineered mouse developed at Harvard, which carries several mouse oncogenes and promoter regions, making it highly susceptible to tumour formation, ergo a useful model for studying cancer
References in periodicals archive ?
FEMALEMAN_MEETS_ONCOMOUSE: FEMINISM AND TECHNOSCIENCE 49-117 (1997) [herinafter HARA--WAY, MODEST WITNESS] (discussing the patenting of the Harvard OncoMouse that is used to diagnosis certain types of breast cancer).
211) DuPont held an exclusive license for the patent covering the Oncomouse, a genetically engineered mouse that quickly became extremely valuable to this community.
Meanwhile, in the United States the Harvard Oncomouse patent
A lack of access to corporate controlled IP occurs as some companies refuse to license technologies for use, or limit access as in the case of the Dupont oncomouse.
The famous OncoMouse [R] was born, and DuPont, which funded the research, holds the exclusive license to it and all its progeny, though the National Institutes of Health is using the mice for cancer research with the understanding that any commercial application it develops belongs to DuPont.
Many jurisdictions, such as Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxemburg, The Netherlands, Portugal, Spain, Sweden, the United Kingdom, and the United States, have granted a patent on the oncomouse.
More recently, DuPont has engendered controversy in the context of sub-licenses to use oncomouse technology, which DuPont controls as exclusive licensee under a patent owned by Harvard University.
Ya con ese marco juridico la Universidad de Harvard, a finales de la decada de los anos ochenta, recibio la primera patente sobre la vida de un animal; un biologo creo mediante alteracion genetica, lo que ahora se conoce como el oncomouse u oncorraton, un animal susceptible de crear cancer, y que fue beneficiado con la patente 4, 736, 866 del 12 de abril de 1988.
The Oncomouse has tumor-causing genes inserted in its genome so that it can be used for cancer research.
Many US researchers boycotted the genetically engineered, cancer-susceptible Oncomouse (the world's first patented animal) because the patent holder, Harvard University, required potential users to sign over rights to all derivative products.
However, there is currently a national review of the patent system in response to a patent request for the Oncomouse, a mouse with human genes used in cancer testing.
Exceptions to the latter have included polyploid oysters and the so-called oncomouse, a transgenic variety genetically engineered to carry the oncogene so indispensable to modern cancer research.